Altimmune Plunges 51.23% on Disappointing Trial Results

On June 26, 2025, Altimmune's stock price plummeted by 51.23% in pre-market trading, marking a significant downturn for the biotech company.

Altimmune's recent stock volatility can be attributed to several key developments. The company announced that it would disclose top-line results from its 24-week Phase 2b IMPACT trial, which initially boosted investor optimism and led to a surge in after-hours trading. However, the subsequent market reaction suggests that the results may not have met investor expectations, leading to the sharp decline in stock price.

Analysts from H.C. Wainwright and Laidlaw & Company have maintained a positive outlook on Altimmune, with both firms rating the stock as a Buy. H.C. Wainwright set a price target of $15, while Laidlaw & Company aimed for $16. These ratings indicate confidence in the company's long-term prospects, despite the recent market turbulence.